EDINBURGH, Scotland--(BUSINESS WIRE)--IOmet Pharma, a privately-held company focused on cancer immunotherapy and cancer metabolism, will present data demonstrating superior pharmacokinetic / pharmacodynamic (PK/PD) properties in its pre-clinical IDO, TDO and IDO/TDO Dual Inhibitor programs. The data will be presented at the Immunotherapy of Cancer (ITOC) meeting in Munich, Germany on March 25 & 26.
IOmet is developing multiple, distinct novel chemical series of potent, IDO-selective, TDO-selective and dual-acting IDO/TDO inhibitors. IDO (indoleamine-2,3-dioxygenase) and TDO (tryptophan-2,3-dioxygenase), the rate-limiting enzymes in the pathway that metabolises the essential amino acid tryptophan, have emerged as key targets for the pharmaceutical industry in the cancer immunotherapy field. Overexpression of these enzymes has been detected in a variety of cancers, including glioma, melanoma, lung, ovarian and colorectal cancers, and is associated with poor prognosis and survival.
Help employers find you! Check out all the jobs and post your resume.
IOmet is developing multiple, distinct novel chemical series of potent, IDO-selective, TDO-selective and dual-acting IDO/TDO inhibitors. IDO (indoleamine-2,3-dioxygenase) and TDO (tryptophan-2,3-dioxygenase), the rate-limiting enzymes in the pathway that metabolises the essential amino acid tryptophan, have emerged as key targets for the pharmaceutical industry in the cancer immunotherapy field. Overexpression of these enzymes has been detected in a variety of cancers, including glioma, melanoma, lung, ovarian and colorectal cancers, and is associated with poor prognosis and survival.
Help employers find you! Check out all the jobs and post your resume.
